28356949|t|Association between XRCC1 and ERCC1 single-nucleotide polymorphisms and the efficacy of concurrent radiochemotherapy in patients with esophageal squamous cell carcinoma
28356949|a|The aim of the present study was to investigate the association between single-nucleotide polymorphisms (SNPs) in X-ray repair cross-complementing 1-399 (XRCC1-399) or excision repair cross-complementation group 1-118 (ERCC1-118) and the short-term efficacy of radiochemotherapy, tumor metastasis and relapse, as well as the survival time in patients with esophageal squamous cell carcinoma (ESCC). TaqMan probe-based quantitative polymerase chain reaction (qPCR) was conducted to examine the levels of XRCC1-399 and ERCC1-118 SNPs in the peripheral blood of 50 patients with pathologically confirmed ESCC. In addition, the associations between different genotypes and short-term therapeutic efficacy [the complete remission (CR) rate], tumor metastasis and relapse, as well as the survival time following concurrent radiochemotherapy, were determined. A total of 50 ESCC patients who received concurrent radiochemotherapy were enrolled. It was found that the short-term therapeutic efficacy (CR rate) was higher in the group of patients carrying the homozygous mutation of XRCC1-399 (A / A genotype) than in the group of patients without the XRCC1-399 mutation (G / G genotype). In addition, the CR rate was significantly increased in patients carrying one or two ERCC1-118 C alleles (C / C or C / T genotype) compared with patients lacking the C allele (T / T genotype). The differences were statistically significant (A / A vs. G / G, P=0.014; T T vs. C / T + C / C, P=0.040). During the follow-up period, the group of patients carrying the homozygous mutation of XRCC1-399 (A / A genotype) exhibited a markedly reduced risk of metastasis and relapse compared with the group of patients carrying non-mutated XRCC1-399 (G / G genotype; P=0.031). By contrast, ERCC1-118 SNP was not associated with the risk of metastasis and recurrence (P>0.05). The combined results of univariate and multivariate Cox regression analysis showed that the SNP in ERCC1-118 was closely associated with survival time. The mean survival time was significantly prolonged in patients carrying 1 or 2 C alleles (C / C or C / T genotype) compared with patients lacking the C allele (T / T genotype) [T / T vs. C / C, HR =12.96, 95% confidence interval (CI)=3.08-54.61, P<0.001; T T vs. C / T + C / C, HR =11.71, 95% CI =3.06-44.83, P<0.001]. However, XRCC1-399 SNP had no effect on survival time (P>0.05). XRCCl-399 SNP was associated with the short-term therapeutic efficacy (the CR rate) and tumor metastasis / relapse in ESCC patients who received the docetaxel plus cisplatin (TP) regimen -based concurrent radiochemotherapy. By contrast, ERCC1-118 SNP was significantly associated with the short-term therapeutic efficacy (the CR rate) and survival time in ESCC patients who received TP regimen -based concurrent radiochemotherapy.
28356949	0	11	Association	T080	C0439849
28356949	20	25	XRCC1	T028	C1366475
28356949	30	35	ERCC1	T028	C1333355
28356949	36	67	single-nucleotide polymorphisms	T086	C0752046
28356949	76	84	efficacy	T080	C1280519
28356949	88	116	concurrent radiochemotherapy	T061	C3178775
28356949	120	128	patients	T101	C0030705
28356949	134	168	esophageal squamous cell carcinoma	T191	C0279626
28356949	205	216	investigate	T169	C1292732
28356949	221	232	association	T080	C0439849
28356949	241	272	single-nucleotide polymorphisms	T086	C0752046
28356949	274	278	SNPs	T086	C0752046
28356949	283	321	X-ray repair cross-complementing 1-399	T028	C1366475
28356949	323	332	XRCC1-399	T028	C1366475
28356949	337	386	excision repair cross-complementation group 1-118	T028	C1333355
28356949	388	397	ERCC1-118	T028	C1333355
28356949	407	417	short-term	T079	C0443303
28356949	418	426	efficacy	T080	C1280519
28356949	430	447	radiochemotherapy	T061	C0436307
28356949	449	465	tumor metastasis	T191	C0027627
28356949	470	477	relapse	T067	C0035020
28356949	494	507	survival time	T201	C2919552
28356949	511	519	patients	T101	C0030705
28356949	525	559	esophageal squamous cell carcinoma	T191	C0279626
28356949	561	565	ESCC	T191	C0279626
28356949	568	625	TaqMan probe-based quantitative polymerase chain reaction	T063	C3179034
28356949	627	631	qPCR	T063	C3179034
28356949	650	657	examine	T033	C0332128
28356949	662	668	levels	T080	C0441889
28356949	672	681	XRCC1-399	T028	C1366475
28356949	686	695	ERCC1-118	T028	C1333355
28356949	696	700	SNPs	T086	C0752046
28356949	708	724	peripheral blood	T031	C0229664
28356949	731	739	patients	T101	C0030705
28356949	745	759	pathologically	T169	C1521733
28356949	760	769	confirmed	T033	C0750484
28356949	770	774	ESCC	T191	C0279626
28356949	793	805	associations	T080	C0439849
28356949	814	823	different	T080	C1705242
28356949	824	833	genotypes	T032	C0017431
28356949	838	848	short-term	T079	C0443303
28356949	849	869	therapeutic efficacy	T080	C2348767
28356949	875	893	complete remission	T033	C0677874
28356949	895	897	CR	T033	C0677874
28356949	899	903	rate	T081	C1521828
28356949	906	922	tumor metastasis	T191	C0027627
28356949	927	934	relapse	T067	C0035020
28356949	951	964	survival time	T201	C2919552
28356949	975	1003	concurrent radiochemotherapy	T061	C3178775
28356949	1010	1020	determined	T080	C0521095
28356949	1036	1040	ESCC	T191	C0279626
28356949	1041	1049	patients	T101	C0030705
28356949	1063	1091	concurrent radiochemotherapy	T061	C3178775
28356949	1129	1139	short-term	T079	C0443303
28356949	1140	1160	therapeutic efficacy	T080	C2348767
28356949	1162	1164	CR	T033	C0677874
28356949	1165	1169	rate	T081	C1521828
28356949	1189	1194	group	T078	C0441833
28356949	1198	1206	patients	T101	C0030705
28356949	1220	1239	homozygous mutation	T045	C0026882
28356949	1243	1252	XRCC1-399	T028	C1366475
28356949	1254	1255	A	T114,T121,T123	C0001443
28356949	1258	1259	A	T114,T121,T123	C0001443
28356949	1260	1268	genotype	T032	C0017431
28356949	1282	1287	group	T078	C0441833
28356949	1291	1299	patients	T101	C0030705
28356949	1312	1321	XRCC1-399	T028	C1366475
28356949	1322	1330	mutation	T045	C0026882
28356949	1332	1333	G	T114,T121	C0018330
28356949	1336	1337	G	T114,T121	C0018330
28356949	1338	1346	genotype	T032	C0017431
28356949	1366	1368	CR	T033	C0677874
28356949	1369	1373	rate	T081	C1521828
28356949	1378	1401	significantly increased	T081	C4055637
28356949	1405	1413	patients	T101	C0030705
28356949	1434	1443	ERCC1-118	T028	C1333355
28356949	1446	1453	alleles	T028	C0002085
28356949	1455	1456	C	T114	C0010715
28356949	1459	1460	C	T114	C0010715
28356949	1464	1465	C	T114	C0010715
28356949	1468	1469	T	T114,T123	C0040077
28356949	1470	1478	genotype	T032	C0017431
28356949	1480	1488	compared	T052	C1707455
28356949	1494	1502	patients	T101	C0030705
28356949	1515	1516	C	T114	C0010715
28356949	1517	1523	allele	T028	C0002085
28356949	1525	1526	T	T114,T123	C0040077
28356949	1529	1530	T	T114,T123	C0040077
28356949	1531	1539	genotype	T032	C0017431
28356949	1563	1588	statistically significant	T081	C0237881
28356949	1590	1591	A	T114,T121,T123	C0001443
28356949	1594	1595	A	T114,T121,T123	C0001443
28356949	1600	1601	G	T114,T121	C0018330
28356949	1604	1605	G	T114,T121	C0018330
28356949	1616	1617	T	T114,T123	C0040077
28356949	1618	1619	T	T114,T123	C0040077
28356949	1624	1625	C	T114	C0010715
28356949	1628	1629	T	T114,T123	C0040077
28356949	1632	1633	C	T114	C0010715
28356949	1636	1637	C	T114	C0010715
28356949	1660	1676	follow-up period	T033	C0589120
28356949	1682	1687	group	T078	C0441833
28356949	1691	1699	patients	T101	C0030705
28356949	1713	1732	homozygous mutation	T045	C0026882
28356949	1736	1745	XRCC1-399	T028	C1366475
28356949	1747	1748	A	T114,T121,T123	C0001443
28356949	1751	1752	A	T114,T121,T123	C0001443
28356949	1753	1761	genotype	T032	C0017431
28356949	1775	1791	markedly reduced	T080	C0392756
28356949	1792	1796	risk	T078	C0035647
28356949	1800	1810	metastasis	T046	C4255448
28356949	1815	1822	relapse	T067	C0035020
28356949	1823	1831	compared	T052	C1707455
28356949	1841	1846	group	T078	C0441833
28356949	1850	1858	patients	T101	C0030705
28356949	1880	1889	XRCC1-399	T028	C1366475
28356949	1891	1892	G	T114,T121	C0018330
28356949	1895	1896	G	T114,T121	C0018330
28356949	1897	1905	genotype	T032	C0017431
28356949	1930	1939	ERCC1-118	T028	C1333355
28356949	1940	1943	SNP	T086	C0752046
28356949	1952	1967	associated with	T080	C0332281
28356949	1972	1976	risk	T078	C0035647
28356949	1980	1990	metastasis	T046	C4255448
28356949	1995	2005	recurrence	T067	C0034897
28356949	2040	2050	univariate	T062	C0683962
28356949	2055	2091	multivariate Cox regression analysis	T170	C0034980
28356949	2108	2111	SNP	T086	C0752046
28356949	2115	2124	ERCC1-118	T028	C1333355
28356949	2137	2152	associated with	T080	C0332281
28356949	2153	2166	survival time	T201	C2919552
28356949	2172	2190	mean survival time	T081	C0086595
28356949	2195	2208	significantly	T078	C0750502
28356949	2209	2218	prolonged	T079	C0439590
28356949	2222	2230	patients	T101	C0030705
28356949	2247	2248	C	T114	C0010715
28356949	2249	2256	alleles	T028	C0002085
28356949	2258	2259	C	T114	C0010715
28356949	2262	2263	C	T114	C0010715
28356949	2267	2268	C	T114	C0010715
28356949	2271	2272	T	T114,T123	C0040077
28356949	2273	2281	genotype	T032	C0017431
28356949	2283	2291	compared	T052	C1707455
28356949	2297	2305	patients	T101	C0030705
28356949	2318	2319	C	T114	C0010715
28356949	2320	2326	allele	T028	C0002085
28356949	2328	2329	T	T114,T123	C0040077
28356949	2332	2333	T	T114,T123	C0040077
28356949	2334	2342	genotype	T032	C0017431
28356949	2345	2346	T	T114,T123	C0040077
28356949	2349	2350	T	T114,T123	C0040077
28356949	2355	2356	C	T114	C0010715
28356949	2359	2360	C	T114	C0010715
28356949	2362	2364	HR	T081	C2985465
28356949	2377	2396	confidence interval	T081	C0009667
28356949	2398	2400	CI	T081	C0009667
28356949	2423	2424	T	T114,T123	C0040077
28356949	2425	2426	T	T114,T123	C0040077
28356949	2431	2432	C	T114	C0010715
28356949	2435	2436	T	T114,T123	C0040077
28356949	2439	2440	C	T114	C0010715
28356949	2443	2444	C	T114	C0010715
28356949	2446	2448	HR	T081	C2985465
28356949	2461	2463	CI	T081	C0009667
28356949	2496	2505	XRCC1-399	T028	C1366475
28356949	2506	2509	SNP	T086	C0752046
28356949	2514	2523	no effect	T080	C1301751
28356949	2527	2540	survival time	T201	C2919552
28356949	2551	2560	XRCCl-399	T028	C1366475
28356949	2561	2564	SNP	T086	C0752046
28356949	2569	2584	associated with	T080	C0332281
28356949	2589	2599	short-term	T079	C0443303
28356949	2600	2620	therapeutic efficacy	T080	C2348767
28356949	2626	2628	CR	T033	C0677874
28356949	2629	2633	rate	T081	C1521828
28356949	2639	2655	tumor metastasis	T191	C0027627
28356949	2658	2665	relapse	T067	C0035020
28356949	2669	2673	ESCC	T191	C0279626
28356949	2674	2682	patients	T101	C0030705
28356949	2700	2737	docetaxel plus cisplatin (TP) regimen	T061	C1880380
28356949	2745	2773	concurrent radiochemotherapy	T061	C3178775
28356949	2788	2797	ERCC1-118	T028	C1333355
28356949	2798	2801	SNP	T086	C0752046
28356949	2806	2819	significantly	T078	C0750502
28356949	2820	2835	associated with	T080	C0332281
28356949	2840	2850	short-term	T079	C0443303
28356949	2851	2871	therapeutic efficacy	T080	C2348767
28356949	2877	2879	CR	T033	C0677874
28356949	2880	2884	rate	T081	C1521828
28356949	2890	2903	survival time	T201	C2919552
28356949	2907	2911	ESCC	T191	C0279626
28356949	2912	2920	patients	T101	C0030705
28356949	2934	2944	TP regimen	T061	C1880380
28356949	2952	2980	concurrent radiochemotherapy	T061	C3178775